Gland Pharma Limited ’s Board has approved the re-appointment of Mr. Udo Johannes Vetter and the appointment of Mr. William Robert Keller as Independent Directors, following the resignation of Mr. Satyanarayana Murthy Chavali due to a potential conflict of interest. The changes, effective June 15, 2026, necessitate shareholder approval through postal ballot and e-voting under SEBI Listing Regulations. The Board has also realigned its committee compositions to comply with regulatory requirements.

Mr. Udo Johannes Vetter has been re-appointed for a second term of five consecutive years, effective from July 21, 2026, to July 20, 2031. Mr. William Robert Keller was appointed as an Additional Director (Non-Executive - Independent Director) effective June 15, 2026. Shareholder approval is required for both appointments under Regulation 17(1A) and 25(2A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Mr. Satyanarayana Murthy Chavali resigned as an Independent Director effective the close of business hours on June 15, 2026. The resignation was attributed to a potential conflict of interest arising from a company where he is a Promoter and Director proposing to enter a business segment overlapping with Gland Pharma’s future activities. He confirmed no other material reasons for his departure.

Consequent to the resignation, Mr. Essaji Goolam Vahanvati was appointed as a Director on the Board of Gland Pharma International Pte. Ltd, a material subsidiary, effective June 15, 2026. The Board committees were reconstituted to reflect the changes in directorship.

The Audit Committee now includes Mr. Essaji Goolam Vahanvati as Chairman, along with Mr. William Robert Keller and Mr. Udo Johannes Vetter. The Nomination & Remuneration Committee is chaired by Mr. Udo Johannes Vetter, with members Mr. Essaji Goolam Vahanvati, Mr. William Robert Keller, and Ms. Wei Huang. The Stakeholders' Relationship Committee is chaired by Mr. Udo J Vetter.

Board Committee Composition

Gland Pharma Limited has requested its shareholders to register or update their email addresses to ensure the delivery of general meeting notices, annual reports, and other statutory communications in electronic form. The company issued this notice to comply with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with the publication appearing in newspapers on June 10, 2026.

The company stated that shareholders holding shares in physical mode who have not yet registered or updated their email addresses must do so immediately. These members are required to send their Folio Number and a valid email address to either the company's Registrar and Transfer Agent, MUFG Intime India Private Limited (formerly known as Link Intime India Private Limited), or directly to Gland Pharma Limited via email.

For shareholders holding shares in dematerialised mode, the company has directed them to register or update their email addresses with the Depository Participant where their demat accounts are maintained. This step is necessary to ensure seamless electronic communication regarding corporate actions and statutory documents.

The notice was signed by Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer of Gland Pharma Limited, on June 09, 2026. The communication was disseminated to both BSE Limited and the National Stock Exchange of India Limited for their information and records.

Contact Details for Updates